Peritoneal Surface Malignancy Consortium

Join us for our Upcoming PSM Registry Demo in Washington DC on 9/26/26

We plan to convene an initial discussion of trial design proposals on Saturday 9/26/2026 4:00-6:00pm at the Westin City Center in Washington DC, alongside a demo of the registry platform. A zoom option will be available as well.

We are excited to share an important update on the AI-powered PSM (peritoneal surface malignancies) Registry and formally invite you to join the PSM Consortium as we move into our next phase: launching our first registry-based clinical trials.

Over the past year, Yale Surgical Oncology has built and secured full regulatory clearance (IRB #2000041334, Epic approval, TEFCA permission, and data governance committee clearance) for a patient-consented, AI-powered, EHR-based research registry for individuals with PSM. Our platform uses validated LLM-based extraction to curate longitudinal, research-grade clinical, pathologic, radiologic, and genomic data directly from the EHR — dramatically reducing the cost and labor burden that has historically made prospective PSM trials infeasible. The registry is scheduled to go live on 8/25/2026, with at-scale enrollment beginning at Yale on 9/1/2026.

With this infrastructure in place, we are now ready to launch our first registry-based clinical trial using the shared consent framework and IRB approval we’ve already established. We have secured funding to support several such trials, and trial selection will be prioritized on clinical relevance and feasibility of study design.

We like to invite your site to formally join the PSM Consortium as a registry and trial contributor. This includes:

• Access to de-identified registry data curated for clinical trials
• Participation in a once-monthly consortium meeting (virtual), open to all site investigators and study team members
• A designated clinical team member responsible for coordinating patient referrals and enrollment at your site
• Attendance at a dedicated 1-hour meeting every 3 months to review trial data, accrual progress, and data completeness metrics across the consortium
• A shared commitment to our authorship framework, which ensures equitable recognition of participating sites and investigators based on defined contribution criteria

Onboarding to the shared registry infrastructure does not require rebuilding data agreements, consent processes, or IRB protocols from scratch — new sites join under our existing business associate and IRB reliance agreements, significantly reducing the time and resource burden of standard multi-site trial activation.

To ensure rigorous, equitable, and multidisciplinary oversight of trial selection, we are forming trial design committees composed of site investigators from across the PSM Consortium. Each trial design committee will be focused on a particular cancer type. Committees will review and vet proposed trial designs, with our biostatistics team providing formal statistical review of each design prior to adjudication.

We invite you to submit trial proposals that can be implemented into our registry. We are specifically interested in launching trials comparing standard-of-care versus standard-of-care interventions (i.e. surgery vs. chemotherapy, or chemotherapy #1 vs. chemotherapy #2) that can be rapidly rolled out. Trial design examples include step-wedged clustering, crossover, or observational with randomization at an institutional level. Our statistics team will review submitted proposals and are happy to work with you on refining trial concepts.

Please respond to the survey links if you are interested in joining our registry as a trial committee member or PSM registry site participant, or both. Additionally, please let us know if you have a trial proposal you are interested to launch on our registry. We would be glad to schedule a brief call to answer any questions about the registry, trial design process, or consortium commitments.

We are grateful for your partnership in building a scalable, AI-powered framework for prospective research in peritoneal surface malignancies, and we look forward to working together to make trials like this possible our patients.